XML 62 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
BUSINESS SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2014
Segment Reporting [Abstract]  
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross revenues to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross revenues were as follows:
 
 
2014
 
2013
 
2012
McKesson Corporation
 
20
%
 
19
%
 
23
%
Cardinal Health, Inc.
 
12
%
 
14
%
 
19
%
AmerisourceBergen Corporation
 
17
%
 
15
%
 
14
%
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
Selected geographic area information was as follows:
 
 
Total Revenues
 
Property, Plant and Equipment
Dollars in Millions
 
2014
 
2013
 
2012
 
2014
 
2013
United States
 
$
7,716

 
$
8,318

 
$
10,384

 
$
3,686

 
$
3,708

Europe
 
3,592

 
3,930

 
3,706

 
597

 
729

Rest of the World
 
3,459

 
3,295

 
3,204

 
134

 
142

Other(a) 
 
1,112

 
842

 
327

 
—

 
—

Total
 
$
15,879

 
$
16,385

 
$
17,621

 
$
4,417

 
$
4,579


(a)
Other total revenues include royalties and other alliance-related revenues for products not sold by our regional commercial organizations.
Revenue from External Customers by Products and Services [Table Text Block]
Total revenues of key products were as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2014
 
2013
 
2012
Virology
 
 
 
 
 
 
Baraclude (entecavir)
 
$
1,441

 
$
1,527

 
$
1,388

Hepatitis C Franchise(a)
 
256

 
—

 
—

Reyataz (atazanavir sulfate)
 
1,362

 
1,551

 
1,521

Sustiva (efavirenz) Franchise(b)
 
1,444

 
1,614

 
1,527

Oncology
 
 
 
 
 
 
Erbitux* (cetuximab)
 
723

 
696

 
702

Opdivo (nivolumab)
 
6

 
—

 
—

Sprycel (dasatinib)
 
1,493

 
1,280

 
1,019

Yervoy (ipilimumab)
 
1,308

 
960

 
706

Neuroscience
 
 
 
 
 
 
Abilify* (aripiprazole)(c)
 
2,020

 
2,289

 
2,827

Immunoscience
 
 
 
 
 
 
Orencia (abatacept)
 
1,652

 
1,444

 
1,176

Cardiovascular
 
 
 
 
 
 
Eliquis (apixaban)
 
774

 
146

 
2

Diabetes Alliance(d)
 
295

 
1,683

 
972

Mature Products and All Other(e)
 
3,105

 
3,195

 
5,781

Total Revenues
 
$
15,879

 
$
16,385

 
$
17,621


(a)
Includes Daklinza (daclatasvir) revenues of $201 million and Sunvepra (asunaprevir) revenues of $55 million in 2014.
(b)
Includes alliance and other revenues of $1,255 million in 2014, $1,366 million in 2013 and $1,267 million in 2012.
(c)
Includes alliance and other revenues of $1,778 million in 2014, $1,840 million in 2013 and $2,340 million in 2012.
(d)
Includes Bydureon* (exenatide extended-release for injectable suspension), Byetta* (exenatide), Farxiga*/Xigduo* (dapagliflozin/dapagliflozin and metformin hydrochloride), Onglyza*/Kombiglyze* (saxagliptin/saxagliptin and metformin), Myalept* (metreleptin) and Symlin* (pramlintide acetate). BMS sold its diabetes business to AstraZeneca on February 1, 2014.
(e)
Includes Plavix* (clopidogrel bisulfate) revenues of $208 million in 2014, $258 million in 2013 and $2,547 million in 2012. Additionally, includes Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide) revenues of $211 million in 2014, $231 million in 2013 and $503 million in 2012.